A5074583317- Animal testing and alternatives
- Schizophrenia research and treatment
- Diet and metabolism studies
- Estrogen and related hormone effects
- Bipolar Disorder and Treatment
- Health Systems, Economic Evaluations, Quality of Life
- Veterinary Pharmacology and Anesthesia
- Intraocular Surgery and Lenses
- Computational Drug Discovery Methods
- Monoclonal and Polyclonal Antibodies Research
- HER2/EGFR in Cancer Research
University of Buenos Aires
2019-2024
Centro Científico Tecnológico - San Juan
2023-2024
Experimental Medicine and Biology Institute
2021
Consejo Nacional de Investigaciones Científicas y Técnicas
2021
Institute of Pharmacology
2020
Istituto di Farmacologia Traslazionale
2019
Medicina
2019
Between 25% and 50% of patients suffering from treatment-resistant schizophrenia fail to achieve a clinical response with clozapine. The rapid identification treatment this subgroup represents challenge for healthcare practice.To evaluate the relationship between metabolic alterations clozapine.A multicenter, observational, case-control study was performed. Patients diagnosed treated clozapine were eligible (minimum dose 400 mg/d at least 8 weeks and/or plasma levels ⩾ 350 µg/mL). According...
Para la aprobación, registro y comercialización de medicamentos, agroquímicos, productos uso doméstico sustancias cosméticas es necesario estudiar e informar al organismo regulador potencial toxicidad. Por motivos éticos económicos, en los últimos años se ha disminuido utilización animales experimentación fomentado el desarrollo metodologías alternativas. En proceso migración, OCDE validó procedimientos para evaluar irritación corrosión ocular dérmica, mutagenicidad, fototoxicidad,...
Abstract Background 30% patients suffering from schizophrenia fail to obtain therapeutic benefit even after two appropriate antipsychotic trials and are considered resistant. The recommended treatment in these cases is clozapine (CLZ), but only 40% of with resistant show clinical response, a condition called ultra-resistance (UR) defined as the lack response 8 12 weeks at least 400 mg/day or plasma levels ≥ 350 ng/ml. objective present study identify factors associated UR group Argentina....
Abstract Triple negative breast cancer (TNBC) has poor prognosis and neither established biomarkers nor therapeutic targets. On the one hand androgen receptor (AR), a steroid hormone (SR) which is expressed in 10-53% of TNBC proved to be critical for BC proliferation, been proposed as new target TNBC. other hand, we others have shown that membrane ErbB-2 migrates nucleus (nuclear ErbB-2, NErbB-2) where it binds DNA at HER-2 associated sequences (HAS) regulate proliferation migration. Since...